SEHK:2137
SEHK:2137Biotechs

Asian Penny Stocks To Watch In October 2025

As Asian markets navigate a complex economic landscape marked by global uncertainties and regional developments, investors are increasingly turning their attention to under-the-radar opportunities. Penny stocks, though an older term, still capture the essence of investing in smaller or newer companies that may offer significant growth potential at lower price points. By focusing on those with strong financial health and clear growth prospects, investors can uncover hidden gems that might...
SEHK:2186
SEHK:2186Pharmaceuticals

Does the Recent 7.7% Price Jump Signal a New Outlook for Luye Pharma Group in 2025?

If you are looking at Luye Pharma Group’s stock and wondering whether now is the right time to buy, hold, or even take some profit, you are not alone. The company’s recent price swings have caught the attention of both seasoned investors and cautious newcomers. In just the past week, the stock climbed by an impressive 7.7%, a move that stands out after a volatile month that saw shares drop by 7.4%. Despite these ups and downs, long-term holders are likely noticing the big picture. Since the...
SEHK:998
SEHK:998Banks

Does CITIC Bank’s Strong 2025 Rally Signal More Room for Growth?

If you're eyeing China CITIC Bank's stock and wondering if now is the right time to make a move, you're not alone. Many investors are trying to size up what’s driving this bank’s surprising momentum, especially in the midst of shifting market sentiment. Despite some recent softness, with a drop of 1.8% over the past week and a 5.7% slip over the last month, the longer-term numbers tell a different story. Year to date, China CITIC Bank’s stock is up a strong 26.5%, and if you zoom out further,...
SEHK:939
SEHK:939Banks

Does China Construction Bank’s Stock Offer Value After Recent Price Dip and Regulatory Developments?

Wondering what to do with China Construction Bank stock? You are definitely not alone. Whether you have watched its price climb over 100% in the last three or five years, or you are noting the recent dip over the past month, the ride has been anything but dull. Year to date, shares are still up an impressive 20.7%, and over the past year, investors have enjoyed a hefty 26.1% return. Even with a slide of -5.0% in the last 30 days, long-term performance shows plenty of resilience and perhaps...
SEHK:762
SEHK:762Telecom

Is China Unicom Ready for a Rebound After Its 22% Rally in 2025?

If you are wondering what to do with China Unicom (Hong Kong) stock right now, you are not alone. The company has delivered some eye-catching returns over the past few years, and it is on the minds of investors looking for value and stability in a dynamic market. The numbers speak for themselves. While the share price is flat over the past week and down 6.5% over the last month, it is up an impressive 22.3% year-to-date and 21.1% over the last year. Zoom out a bit further and China Unicom...
SEHK:1788
SEHK:1788Capital Markets

Has Guotai Junan International's (SEHK:1788) Share Buyback Strategy Enhanced Its Long-Term Value Proposition?

Between January 1 and May 22, 2025, Guotai Junan International Holdings completed its announced share buyback programme, repurchasing a total of 28,886,000 shares for HK$26.73 million, representing 0.3% of its outstanding shares. This recent completion highlights management’s commitment to capital management and signals ongoing confidence in the business's long-term value proposition. We will examine how the company’s disciplined approach to capital allocation through share repurchases...
SEHK:780
SEHK:780Hospitality

How Does Tongcheng Travel Stack Up After Strong 2025 Performance and Sector Growth?

If you have been keeping an eye on Tongcheng Travel Holdings, you know it is one of those stocks that sparks as many debates as it does interest. Are you looking at a unique opportunity or something you should cross off your watchlist? Let’s unpack what’s actually happening beneath the surface, especially with so many investors trying to decode its potential. Looking at the returns, Tongcheng Travel is hardly a sleeper pick. Over the past year, the stock is up 9.5%, and its year-to-date gain...
SEHK:1177
SEHK:1177Pharmaceuticals

Advancing Oral GLP-1 and Oncology Trials Might Change The Case For Investing In Sino Biopharm (SEHK:1177)

In late September 2025, Sino Biopharmaceutical announced significant progress in its R&D pipeline, enrolling first patients in two global early-stage oncology trials and receiving Chinese regulatory acceptance for an innovative oral GLP-1 receptor agonist targeting type 2 diabetes. These milestones underscore the company's drive to expand into both high-value oncology and metabolic disease markets with potentially first-in-class therapies. We'll explore how advancing a proprietary oral GLP-1...
SEHK:6699
SEHK:6699Medical Equipment

How Does Angelalign Stack Up After Recent 10% Drop and Industry Shifts in 2025?

If you have Angelalign Technology on your radar and are weighing whether its current price tag offers genuine value or added risk, you are in good company. The stock has been anything but boring lately. After a modest 3.6% gain over the past week, Angelalign is still looking to recover from a bruising 10.4% slide over the last 30 days. Despite this recent volatility, the stock sits up 11.4% year-to-date. However, the longer-term one-year return looks less appealing at -13.1%. For investors...